HY-D1601-10mg
|
MedChemexpress LLC
|
N-Aminofluorescein [CAS 98907-26-7]
|
|
|
|
HY-D1601-25mg
|
MedChemexpress LLC
|
N-Aminofluorescein [CAS 98907-26-7]
|
|
|
|
HY-D1601-5mg
|
MedChemexpress LLC
|
N-Aminofluorescein [CAS 98907-26-7]
|
|
|
|
HY-103332-10mg
|
MedChemexpress LLC
|
N-Arachidonylglycine [CAS 179113-91-8]
|
|
COVID-19-immunoregulation
|
|
HY-103332-100mg
|
MedChemexpress LLC
|
N-Arachidonylglycine [CAS 179113-91-8]
|
|
COVID-19-immunoregulation
|
|
HY-103332-25mg
|
MedChemexpress LLC
|
N-Arachidonylglycine [CAS 179113-91-8]
|
|
COVID-19-immunoregulation
|
|
HY-103332-5mg
|
MedChemexpress LLC
|
N-Arachidonylglycine [CAS 179113-91-8]
|
|
COVID-19-immunoregulation
|
|
HY-103332-50mg
|
MedChemexpress LLC
|
N-Arachidonylglycine [CAS 179113-91-8]
|
|
COVID-19-immunoregulation
|
|
HY-124754-10mg
|
MedChemexpress LLC
|
Navacaprant [CAS 2244614-14-8]
|
|
Metabolism-protein/nucleotide metabolism
|
|
HY-124754-5mg
|
MedChemexpress LLC
|
Navacaprant [CAS 2244614-14-8]
|
|
Metabolism-protein/nucleotide metabolism
|
|
HY-124754-50mg
|
MedChemexpress LLC
|
Navacaprant [CAS 2244614-14-8]
|
|
Metabolism-protein/nucleotide metabolism
|
|
HY-124754-1mL
|
MedChemexpress LLC
|
Navacaprant [CAS 2244614-14-8] (10mM in DMSO)
|
|
Metabolism-protein/nucleotide metabolism
|
|
HY-D0718-10mg
|
MedChemexpress LLC
|
Nile Red [CAS 7385-67-3]
|
|
|
|
HY-D0718-100mg
|
MedChemexpress LLC
|
Nile Red [CAS 7385-67-3]
|
|
|
|
HY-D0718-5mg
|
MedChemexpress LLC
|
Nile Red [CAS 7385-67-3]
|
|
|
|
HY-D0718-50mg
|
MedChemexpress LLC
|
Nile Red [CAS 7385-67-3]
|
|
|
|
HY-D0718-500mg
|
MedChemexpress LLC
|
Nile Red [CAS 7385-67-3]
|
|
|
|
HY-D0718-1mL
|
MedChemexpress LLC
|
Nile Red [CAS 7385-67-3] (10mM in DMSO)
|
|
|
|
HY-P99763-1mg
|
MedChemexpress LLC
|
Ociperlimab [CAS 2342597-93-5]
|
|
|
|
HY-P99763-10mg
|
MedChemexpress LLC
|
Ociperlimab [CAS 2342597-93-5]
|
|
|
|
HY-P99763-5mg
|
MedChemexpress LLC
|
Ociperlimab [CAS 2342597-93-5]
|
|
|
|
HY-114226-10mg
|
MedChemexpress LLC
|
Olutasidenib [CAS 1887014-12-1]
|
|
Cancer-programmed cell death
|
|
HY-114226-100mg
|
MedChemexpress LLC
|
Olutasidenib [CAS 1887014-12-1]
|
|
Cancer-programmed cell death
|
|
HY-114226-25mg
|
MedChemexpress LLC
|
Olutasidenib [CAS 1887014-12-1]
|
|
Cancer-programmed cell death
|
|
HY-114226-5mg
|
MedChemexpress LLC
|
Olutasidenib [CAS 1887014-12-1]
|
|
Cancer-programmed cell death
|
|